Safety and Efficacy of CG53135-05 in the Prevention of Oral Mucositis in Patients Receiving Bone Marrow Transplant
Status:
Completed
Trial end date:
2005-12-01
Target enrollment:
Participant gender:
Summary
CG53135-05, a recombinant human fibroblast growth factor-20 (rhFGF-20) protein, is under
investigation for the prevention of oral mucositis. Oral mucositis is a commonly occurring
side effect of high-dose chemotherapy in patients undergoing autologous hematopoietic stem
cell transplant. The objective of this Phase II trial is to evaluate the safety and efficacy
of CG53135-05 when administered as a single dose to patients at risk for developing oral
mucositis.